Comparison of Oral Methylprednisolone and Intratympanic Dexamethasone Treatments for Sudden Sensorineural Hearing Loss

What this Trial Is About

Researchers are evaluating which corticosteroid treatment works better for patients with sudden sensorineural hearing loss: oral methylprednisolone or intratympanic dexamethasone. This phase 4 clinical trial focuses on comparing these two treatment methods to determine which is more effective in improving hearing in affected patients. The study includes adults diagnosed with this sudden hearing loss condition and aims to measure improvement through hearing tests over time. Participants are divided into two groups. One group receives oral methylprednisolone daily for two weeks with a tapering dose schedule starting at 48 mg for the first 7 days and decreasing over the following days. The other group receives intratympanic dexamethasone injections every other day for a total of four doses. These treatments are administered under medical supervision, and patients visit the clinic for evaluations during the first and second weeks, and again at one and two months after treatment begins. During the study, participants will undergo hearing tests called audiometric evaluations to monitor changes in hearing ability at multiple time points: the start of treatment, first week, second week, and at one and two months. Additional assessments include temporal MRI scans. Researchers will track treatment adherence and safety throughout the study period. The overall participation extends over at least two months with scheduled clinic visits and evaluations to assess hearing improvement and treatment effects.

Comparison of the Effectiveness of Oral and Intratympanic Corticosteroid Treatments in Patients Diagnosed With Sudden Sensorineural Hearing Loss